Shockwave Medical Buys Neovasc at USD 100 million valuation
Nasdaq-listed Shockwave Medical, Inc., a pioneer in the treatment of cardiovascular disease, has agreed to buy public company Neovasc Inc., focused on the minimally invasive treatment of refractory angina.
Shockwave expects to complete the transaction in the first half of 2023.
Blake, Cassels & Graydon LLP and Skadden, Arps, Slate, Meagher & Flom LLP are acting as Canadian and U.S. legal counsel to Neovasc, respectively. Fenwick & West LLP and Davies Ward Phillips & Vineberg LLP are acting as U.S. and Canadian legal counsel to Shockwave, respectively.
Goldfarb Seligman advised Shockwave Medical, as local Israeli counsel, led by Corporate partner Adam M. Klein, alongside IP partner Ronen Hausirer, associates Noa Jasovich and Yael Willner and intern Tal Zandman, Co-Head of the Tax Department, Yaron Sever and associate Lidor Almasy; and Labor partner Revital Shprung-Levy.
